Zimmer Biomet (ZBH) Projected to Post Earnings on Thursday

Zimmer Biomet (NYSE:ZBH) will likely be announcing its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $2.30 per share and revenue of $2.01 billion for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same period in the prior year, the firm earned $1.65 EPS. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. On average, analysts expect Zimmer Biomet to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Zimmer Biomet Price Performance

NYSE ZBH opened at $111.25 on Thursday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The firm’s 50 day moving average price is $107.87 and its 200-day moving average price is $108.20. Zimmer Biomet has a 52-week low of $100.67 and a 52-week high of $133.90. The company has a market cap of $22.15 billion, a PE ratio of 21.15, a P/E/G ratio of 1.88 and a beta of 1.02.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be paid a $0.24 dividend. The ex-dividend date is Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.86%. Zimmer Biomet’s dividend payout ratio (DPR) is 18.25%.

Analysts Set New Price Targets

ZBH has been the subject of a number of research analyst reports. Raymond James decreased their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a report on Monday, October 14th. Stifel Nicolaus lifted their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Truist Financial lifted their target price on shares of Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $124.11.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.